| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820660 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 2 days ago) | |
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 6 days ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 6 days ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(23 days ago) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
Dutrebis is owned by Merck Sharp Dohme.
Dutrebis contains Lamivudine; Raltegravir Potassium.
Dutrebis has a total of 9 drug patents out of which 7 drug patents have expired.
Expired drug patents of Dutrebis are:
- US7435734
- US7217713
- US7217713*PED
- US7435734*PED
- US7169780*PED
- US7820660
- US7169780
Dutrebis was authorised for market use on 06 February, 2015.
Dutrebis is available in tablet;oral dosage forms.
Dutrebis can be used as treatment of hiv-1 infection.
The generics of Dutrebis are possible to be released after 11 September, 2029.
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
DUTREBIS family patents
